다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of hepatology : the journal of the European Association for the Study of the Liver, v.29 no.6, 1998년, pp.1010 - 1014
Wedemeyer, H. (aDepartment of Gastroenterology and Hepatology, Medizinische Hochschule Hannover,, Hannover, Germany) , Caselmann, W.H. , Manns, M.P.
초록이 없습니다.
N Engl J Med Hoofnagle 336 347 1997 10.1056/NEJM199701303360507 The treatment of chronic viral hepatitis
Hepatology Lindsay 26 71S 1997 10.1002/hep.510260713 Therapy of hepatitis C: overview
Science Sidwell 177 705 1972 10.1126/science.177.4050.705 Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl- 1,2,4-triazole-3-carboxamide
Pediatr Pulmonol Edell 25 154 1998 10.1002/(SICI)1099-0496(199803)25:3<154::AID-PPUL4>3.0.CO;2-M Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report
Rev Infect Dis Patterson 12 1332 1990 10.1093/clinids/12.6.1139 Molecular action of ribavirin
J Clin Invest Heagy 87 1916 1991 10.1172/JCI115217 Inhibition of immune functions by antiviral drugs
Transplant Proc Jolley 20 703 1988 Longterm skin allograft survival by combined therapy with suboptimal dose of cyclosporine and ribavirin
Ann N Y Acad Sci Sidwell 284 239 1977 10.1111/j.1749-6632.1977.tb21956.x Effect of ribavirin on viral hepatitis in laboratory animals
Science Vogt 235 1376 1987 10.1126/science.2435003 Ribavirin antagonizes the effect of azido-thymidine on HIV replication
J Immunol Ning 160 3487 1998 10.4049/jimmunol.160.7.3487 Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
Annu Rev Immunol Chisari 13 29 1995 10.1146/annurev.iy.13.040195.000333 Hepatitis B virus immunopathogenesis
Curr Opin Immunol Modlin 5 511 1993 10.1016/0952-7915(93)90031-M Type 2 cytokines and negative immune regulation in human infections
Gastroenterology Botarelli 104 580 1993 10.1016/0016-5085(93)90430-K T-lymphocyte response to hepatitis C virus in different clinical courses of infection
J Immunol Woitas 159 1012 1997 10.4049/jimmunol.159.2.1012 CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes
Immunol Today Allen 18 387 1997 10.1016/S0167-5699(97)01102-X Th1-Th2: reliable paradigm or dangerous dogma?
Hepatology Lechmann 24 790 1996 T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia
Hepatology Bodenheimer 26 473 1997 10.1002/hep.510260231 Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial
J Hepatol Dusheiko 25 591 1996 10.1016/S0168-8278(96)80225-X Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study
Ann Intern Med di Bisceglie 123 897 1995 10.7326/0003-4819-123-12-199512150-00001 Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
J Med Virol Koskinas 45 29 1995 10.1002/jmv.1890450106 Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients
J Hepatol Camps 19 408 1993 10.1016/S0168-8278(05)80550-1 Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon
Hepatology di Bisceglie 16 649 1992 10.1002/hep.1840160307 A pilot study of ribavirin therapy for chronic hepatitis C
Lancet Reichard 337 1058 1991 10.1016/0140-6736(91)91707-2 Ribavirin treatment for chronic hepatitis C
J Viral Hepat Hoofnagle 3 247 1996 10.1111/j.1365-2893.1996.tb00050.x Prolonged therapy of chronic hepatitis C with ribavirin
Pediatr Infect Dis J Long 16 1023 1997 10.1097/00006454-199711000-00004 Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo
J Hepatol di Bisceglie 21 1109 1994 10.1016/S0168-8278(05)80626-9 Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C
Toxic Substances Journal Levine 13 171 1994 Onset and reversibility of ribavirin-induced testicular toxicity in mice
J Hepatol Chemello 23 8 1995 The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
Scand J Infect Dis Braconier 27 325 1995 10.3109/00365549509032725 Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study
Gastroenterology Lai 111 1307 1996 10.1053/gast.1996.v111.pm8898645 Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
Lancet Reichard 351 83 1998 10.1016/S0140-6736(97)06088-1 Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group
Hepatology Poynard 28 387A 1998 An international randomized trial of interferon alfa-2B and ribavirin (Intron A/Rebetol) 48 or 24 weeks vs. interferon alfa-2B Intron A 48 weeks, for first line treatment of chronic hepatitis C [abstract]
Hepatology McHutchison 28 387A 1998 Interferon alfa 2b alone or in combination with ribavirin in naive chronic HCV patients: a US multicentre trial [abstract]
Gastroenterology Brillanti 107 812 1994 10.1016/0016-5085(94)90131-7 A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
J Hepatol Chemello 28 109 1998 10.1016/S0168-8278(98)80628-4 Retreatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination therapy [abstract]
J Med Virol Schvarcz 46 43 1995 10.1002/jmv.1890460110 Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
Hepatology Davis 26 247A 1997 Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone [abstract]
J Hepatol Schalm 26 961 1997 10.1016/S0168-8278(97)80103-1 Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers
J Viral Hepat Bellobuono 4 185 1997 10.1046/j.1365-2893.1997.00142.x Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial
Ital J Gastroenterol Scotto 28 505 1996 Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone
Z Gastroenterol Wedemeyer 36 819 1998 Re-treatment of chronic hepatitis C with interferon alpha and ribavirin in non-responders to interferon alpha monotherapy - analysis of the own experience and review of the literature
J Hepatol Brillanti 28 114 1998 10.1016/S0168-8278(98)80649-1 Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C [abstract]
Hepatology Boker 25 203 1997 10.1053/jhep.1997.v25.pm0008985291 Long-term outcome of hepatitis C virus infection after liver transplantation
Transplantation Rosen 62 1773 1996 10.1097/00007890-199612270-00015 Graft loss following liver transplantation in patients with chronic hepatitis C
N Engl J Med Gane 334 815 1996 10.1056/NEJM199603283341302 Long-term outcome of hepatitis C infection after liver transplantation
Hepatology Shuhart 26 1646 1997 10.1002/hep.510260638 Histological and clinical outcome after liver transplantation for hepatitis C
Hepatology Bizollon 26 500 1997 10.1002/hep.510260236 Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
Hepatology Feray 22 1084 1995 10.1002/hep.1840220411 An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection
Hepatology Wright 20 773 1994 10.1002/hep.1840200402 Interferon-alpha therapy for hepatitis C virus infection after liver transplantation
Intervirology Caselmann 40 394 1997 10.1159/000150571 Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C
Arch Virol Alt 142 589 1997 10.1007/s007050050105 Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation
Hepatology Alt 22 707 1995 Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.